Maze Compass News Today

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the U.S. Federal Trade Commission (FTC) has filed a complaint seeking to block Sanofi’s exclusive worldwide license agreement for Maze’s glycogen synthase 1 (GYS1) pro...

Data Presented During ASN Kidney Week 2023 Demonstrate Significant Reversal of Albuminuria in Chronic Disease ModelFirst-in-Human Trial of MZE829 Development Candidate Anticipated to Begin by End of 2023SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new p...

Developers of cardiovascular drugs hope to disrupt newly identified molecular mechanisms by deploying highly specific small-molecule drugs and gene therapies